Bifidobacterium animalis subsp. lactis B94

Bifidobacterium animalis subsp. lactis B94 is a probiotic strain that enhances H. pylori eradication therapy in children through competitive exclusion and antimicrobial peptide production. This specific strain modulates gut microbiota composition and reduces gastrointestinal inflammation.

Origin & History

Bifidobacterium animalis subsp. lactis B94 is a specific strain of probiotic bacterium isolated from dairy sources, characterized through whole-genome sequencing and deposited at the Centraalbureau voor Schimmelcultures (CBS-118529). This gram-positive, anaerobic bacterium is produced via fermentation processes typical for probiotic strains and belongs to the B. lactis monophyletic taxon.

Historical & Cultural Context

No historical or traditional medicine use is documented for Bifidobacterium animalis subsp. lactis B94, as it is a modern, strain-specific probiotic isolated for clinical applications. Unlike herbs used in ancient systems like Ayurveda or TCM, B94 represents contemporary probiotic science without traditional precedent.

Health Benefits

• Improves H. pylori eradication in children when used as adjuvant therapy (pooled relative risk 1.23, moderate evidence from multiple pediatric studies)
• May help manage constipation in adults with Prader-Willi syndrome (preliminary evidence from crossover trial protocol)
• Reduces inflammatory markers TNF-α, iNOS, and COX-2 in colitis models (animal studies only)
• Modulates immune response by increasing IFN-γ/IL-4 ratio and IL-10 production (in vitro human cell studies)
• Inhibits pathogenic bacteria including Listeria, E. coli, and Salmonella typhimurium (preclinical evidence)

How It Works

B. animalis subsp. lactis B94 produces bacteriocins and short-chain fatty acids that inhibit pathogenic bacteria growth through competitive exclusion. The strain enhances mucosal barrier function by increasing tight junction proteins and stimulating secretory IgA production. It modulates immune responses through Toll-like receptor signaling pathways, reducing pro-inflammatory cytokines like TNF-α and IL-6.

Scientific Research

A randomized, double-blind, placebo-controlled crossover trial (n=36 adults with Prader-Willi syndrome) evaluated B. lactis B94 for constipation over 4-week treatment periods (PMID: 29703235; NCT03277157), though completion outcomes are not detailed. In pediatric populations (n=262 across studies), B. lactis B94 as adjuvant to triple therapy showed significant improvement in H. pylori eradication rates.

Clinical Summary

Multiple pediatric studies demonstrate that B94 as adjuvant therapy improves H. pylori eradication rates with a pooled relative risk of 1.23, representing moderate-quality evidence. A crossover trial protocol suggests potential benefits for constipation management in adults with Prader-Willi syndrome, though this remains preliminary evidence. Studies typically involve 50-200 participants over 4-12 week intervention periods. Evidence for inflammatory marker reduction exists but requires larger confirmatory trials.

Nutritional Profile

As a probiotic microorganism, Bifidobacterium animalis subsp. lactis B94 does not contribute meaningful macronutrients or micronutrients in the conventional dietary sense, as it is delivered in very small quantities (typically 1×10^9 to 1×10^10 CFU per dose). The primary bioactive components are structural and metabolic in nature: (1) Exopolysaccharides (EPS) produced by B94 strains, which interact with gut epithelial toll-like receptors and modulate mucosal immunity; (2) Short-chain fatty acids (SCFAs), particularly acetate and lactate, generated as fermentation metabolites in the colon — acetate production is a hallmark of Bifidobacterium metabolism, typically in the micromolar-to-low-millimolar range per gram of fermented substrate; (3) Cell wall components including lipoteichoic acids and peptidoglycans, which serve as microbe-associated molecular patterns (MAMPs) influencing NF-κB signaling and downstream cytokine modulation (directly relevant to observed reductions in TNF-α, iNOS, COX-2); (4) Bacteriocin-like inhibitory substances (BLIS) that may contribute to competitive exclusion of pathogens including H. pylori. The organism also produces B-group vitamins (notably folate/B9 and riboflavin/B2) in trace quantities as metabolic byproducts, consistent with other B. animalis subsp. lactis strains, though B94-specific quantification data are not published. Bioavailability of metabolic outputs is local (colonic) rather than systemic for most compounds; survival through gastric acid varies but B. animalis subsp. lactis strains as a group demonstrate relatively high acid and bile tolerance compared to other Bifidobacterium species, supporting viable delivery to the lower GI tract. Caloric contribution per dose is negligible (<1 kcal).

Preparation & Dosage

Clinically studied dosages for B. lactis B94 are not explicitly quantified in available human trials, though protocols indicate daily oral consumption in powder or fermented forms for 4 weeks. CFU counts and standardized dosing information are not provided in the research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other Bifidobacterium strains, Lactobacillus acidophilus, Prebiotics (FOS/GOS), Saccharomyces boulardii, Zinc

Safety & Interactions

B. animalis subsp. lactis B94 is generally well-tolerated with minimal reported side effects in clinical trials. Mild gastrointestinal symptoms like bloating may occur during initial supplementation. No significant drug interactions have been documented, though timing with antibiotic therapy should be considered. Safety during pregnancy and breastfeeding has not been established through controlled studies.